Ipilimumab and immune-mediated adverse events: A case report of anti-CTLA4 induced ileitis

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Venditti, Olga ^a   De Lisi, Delia ^a   Caricato, Marco ^a   Caputo, Damiano ^a   Capolupo, Gabriella Teresa ^a   Taffon, Chiara ^a   Pagliara, Elisa ^b   Battisi, Sofia ^b   Frezza, Anna Maria ^a   Onetti Muda, Andrea ^a   Tonini, Giuseppe ^a   Santini, Daniele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Department of General Surgery ^*  (Italy)

Author keywords

Ileitis; Immune mediated adverse events; Ipilimumab; Melanoma

Indexed keywords

B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; IPILIMUMAB; METHYLPREDNISOLONE; PREDNISONE; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ANTIBODY TITER; ARTICLE; ASTHENIA; BLOOD CLOTTING DISORDER; BRAF GENE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CARCINOMATOSIS; CASE REPORT; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE SEVERITY; EPIGENETICS; ERYTHROCYTE TRANSFUSION; EXON; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEITIS; IMMUNE MEDIATED ILEITIS; IMMUNE MEDIATED ILIETIS; IMMUNOPATHOLOGY; INFLAMMATORY INFILTRATE; INTESTINE BIOPSY; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTE PROLIFERATION; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA; PERITONEAL CARCINOMATOSIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; T LYMPHOCYTE ACTIVATION; TERMINAL ILEUM; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TUMOR LOCALIZATION; TUMOR VOLUME; CHEMICALLY INDUCED; MELANOMA; METASTASIS; PATHOLOGY; PERSONALIZED MEDICINE; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; ILEITIS; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PRECISION MEDICINE; SKIN NEOPLASMS;

EID: 84928751927     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1074-7     Document Type: Article

References (12)

1. Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatol Treat. 2014;25:401-8.
2. Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200:W468-74.
3. Barbieri A, Palma G, Rosati A, Giudice A, Falco A, Petrillo A, et al. Role of endothelial nitric oxide synthase (eNOS) in chronic stress-promoted tumour growth. J Cell Mol Med. 2012;16:920-6.
4. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, et al. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J Investig Dermatol. 2008;128:957-71.
5. Addeo R, Zappavigna S, Luce A, Facchini S, Caraglia M. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opin Drug Saf. 2013;12:729-40.
6. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Sci (New York, NY. 1996;271:1734-6.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
8. Geboes K. Histopathology of Crohn's disease and ulcerative colitis. In: Satsangi J, Sutherland L, editors. Inflammatory Bowel Disease. 4th ed. London: Harcourt; 2003. p. 210-28.
9. Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol. 2004;20:318-27.
10. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.
11. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol OffJ Am Soc Clin Oncol. 2005;23:741-50.
12. Breunis WB, Tarazona Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ. Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immun (Hagerstown Md 1997. 2008;31:586-90.